Compare MLAB & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLAB | SGMT |
|---|---|---|
| Founded | 1982 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 719.9M | 761.6M |
| IPO Year | 1995 | 2021 |
| Metric | MLAB | SGMT |
|---|---|---|
| Price | $121.89 | $9.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $117.50 | $27.91 |
| AVG Volume (30 Days) | 69.6K | ★ 1.2M |
| Earning Date | 11-09-2026 | 11-16-2026 |
| Dividend Yield | ★ 0.50% | N/A |
| EPS Growth | ★ 436.11 | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | $2.14 | N/A |
| Revenue Next Year | $6.45 | N/A |
| P/E Ratio | $261.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $69.51 | $4.50 |
| 52 Week High | $144.35 | $11.45 |
| Indicator | MLAB | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 42.35 | 51.22 |
| Support Level | $120.65 | $8.54 |
| Resistance Level | $132.70 | $11.33 |
| Average True Range (ATR) | 4.57 | 0.62 |
| MACD | -0.34 | 0.15 |
| Stochastic Oscillator | 7.08 | 65.25 |
Mesa Laboratories Inc manufactures life sciences tools and critical quality control solutions. It operates in four divisions: i) Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. ii) Clinical Genomics division develops, manufactures, and sells sensitive, low-cost, high-throughput genetic analysis tools and related consumables. iii) The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. iv) The Calibration Solutions division develops, manufactures, sells, and services quality control products.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.